<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570193</url>
  </required_header>
  <id_info>
    <org_study_id>PBS-100-388</org_study_id>
    <nct_id>NCT00570193</nct_id>
  </id_info>
  <brief_title>Photodynamic and Pharmacologic Treatment of CNV</brief_title>
  <acronym>PBS</acronym>
  <official_title>Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mid-Atlantic Retina Consultations, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mid-Atlantic Retina Consultations, Inc.</source>
  <brief_summary>
    <textblock>
      The goal of this pilot study is to validate the use of the combination of Lucentis
      (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization
      (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a
      volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and
      as a tool for determining the need for retreatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual change</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ranibizumab (Lucentis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verteporfin (Visudyne)</intervention_name>
    <description>Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Visudyne = verteporfin</other_name>
    <other_name>Lucentis = ranibizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab (Lucentis)</intervention_name>
    <description>ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&amp;37 per study protocol</description>
    <arm_group_label>II</arm_group_label>
    <other_name>Lucentis = ranibizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All previously untreated CNV secondary to MD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil M Jabbour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mid-Atlantic Retina Consultations</affiliation>
  </overall_official>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 22, 2013</submitted>
    <returned>June 6, 2013</returned>
    <submitted>June 18, 2013</submitted>
    <returned>July 16, 2013</returned>
    <submitted>October 24, 2013</submitted>
    <returned>December 12, 2013</returned>
    <submitted>December 12, 2013</submitted>
    <returned>January 27, 2014</returned>
    <submitted>October 24, 2014</submitted>
    <returned>October 29, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

